Articles tagged with Cell Transplantation
CPX-351 significantly improved 100-day mortality rates and overall survival in older untreated secondary AML patients receiving hematopoietic cell transplants. The treatment also demonstrated better median overall survival compared to standard 7+3 cytarabine and daunorubicin therapy.
Researchers at Lund University have made a significant breakthrough in producing high-quality dopamine neurons using stem cells. The study has identified key markers that correlate with successful transplantation and graft function, enabling a more accurate methods for producing dopamine cells for clinical use.
Researchers successfully integrated transplanted embryonic nerve cells into the visual cortex of adult mice, demonstrating functional connectivity and restoration of network function. This breakthrough holds promise for treating acquired brain diseases, including neurodegenerative illnesses and stroke-induced damage.
A study found that corneal cells' softness indicates their potential for stem-like activity, enabling rapid and cost-effective enrichment of limbal stem cells. This biomarker could improve clinical success rates for corneal transplant patients with naturally low limbal stem cell percentages.
Huntington's disease, a hereditary neurodegenerative disorder, is characterized by the loss of medium spiny neurons and motor control problems. A new award will support research to develop a stem cell-based therapy that swaps sick brain cells for healthy ones.
Researchers have found a way to restore youthful DNA length in aging cardiac stem cells, improving their ability to form new blood vessels and regenerate heart tissue. The treatment uses a drug to temporarily wake up the cells, making them more responsive to low-oxygen conditions.
A recent study found that cord blood transplants may be the best option for high-risk leukemia patients, offering a lower risk of relapse compared to traditional transplants. Researchers at Fred Hutchinson Cancer Center discovered that these patients have better outcomes against leukemia and related bone marrow disorders.
Researchers found that stem cell transplant can accelerate cellular aging in patients with blood cancer, increasing the molecular age by up to three times pre-transplant levels. The study's findings may help physicians predict patient risk and benefit associated with the treatment.
Researchers found that transplantation of human placental stem cells into diabetic rats improved blood flow and reduced critical limb ischemia, a condition leading to diabetic foot and amputation. The study suggests that mesenchymal stem cells have the potential to treat diabetes-related complications.
A recent study published in Nature Communications found that eliminating dendritic cells from transplanted organs can prolong transplant survival by reducing T cell proliferation. This breakthrough could lead to new methods for preventing or treating organ transplant rejection without compromising the patient's immune defenses.
A nationwide study found that bone marrow-derived stem cells improved psychological well-being and reduced graft-vs.-host disease symptoms in transplant recipients. These patients were also more likely to return to work after five years.
Researchers found that bilirubin supplementation significantly decreased islet cell death after isolation and nutrient deprivation. The study also showed that bilirubin suppressed the release of damage-associated molecular patterns (DAMPs), which are foreign cell-fighting immune cells.
Researchers have devised a method to conduct blood stem cell transplantation without the use of chemotherapy or radiotherapy. This technique uses antibodies to deplete blood-forming stem cells, allowing transplanted blood stem cells from a donor to take up residence in the bone marrow and generate a new immune system.
Researchers at Cardiff University are exploring a potential new treatment for human temporal lobe epilepsy by transplanting immature neuron cells into the brain. The project, funded by Epilepsy Research UK, aims to develop this cell transplantation treatment and potentially lead to clinical trials in the next 3-5 years.
A randomized Phase III study found nearly 81% of patients in the inotuzumab ozogamicin group achieved complete remission, compared to 31-41% with standard therapies. The drug enabled 41% of patients to proceed with stem cell transplants, increasing their chances of a curative treatment.
A Phase 3 clinical trial found that patients with high-risk neuroblastoma who received two autologous stem-cell transplants had higher event-free and overall survival rates compared to those who underwent a single transplant. The study also showed improved outcomes when immunotherapy was added to the treatment regimen.
A two-year clinical study found that CD34+ cells significantly reduced angina frequency in patients resistant to other therapies. The treatment demonstrated persistent improvement in angina and a trend towards decreasing major cardiac events, offering new treatment options for 'no option' patients.
Researchers found that transplanting olfactory ensheathing cells into damaged spinal cord areas significantly improves locomotor performance. The study analyzed 49 studies and identified key factors influencing the therapeutic effect, including timing of application and surgical micro-dissection.
Noninvasive cell-tracking methods enable assessment of stem-cell based therapy safety and efficacy. Current tracking methods for transplanted stem cells include reporter-gene based, exogenous contrast label-based, and multimodel imaging techniques.
A recent study found that broad-spectrum antibiotics can raise the risk of complications from stem cell transplantation, including graft-versus-host disease. The study suggests that selecting antibiotics that spare
Researchers developed a new technique to control dopamine-producing cells' activity in the brain. They identified the exact signalling pathway that causes involuntary movements, known as dyskinesia, and found a way to reduce side effects.
Researchers at Lund University have proven that transplanted nerve cells can survive and function in the human brain for many years, restoring normal dopamine production. A study followed a Parkinson's patient whose nerve cells survived for nearly a quarter of a century after transplantation.
A University of Wisconsin-Madison neuroscientist has successfully inserted a genetic switch into nerve cells to regulate dopamine production with designer drugs. This breakthrough could lead to the development of a new Parkinson's disease treatment and expand its application to other conditions.
Researchers found that transplanting liver cells into an extra-hepatic site, such as the intra-mesentery, can help protect against post-operative liver failure and aid in survival of the remaining liver. The study showed improved overall mortality due to acute liver failure in the transplantation group.
Researchers found that neural stem cell transplantation increased M2 microglial proteins, contributing to anti-inflammatory effects and reducing axonal injury. The study suggests a potential therapeutic strategy for treating traumatic brain injury.
Researchers are exploring new treatments for heart failure using transplanted umbilical cord cells, activated endogenous cardiac stem cells, and immune therapy. A clinical trial assessing the safety of allogenic umbilical cord lining sub-epithelial cells is also underway.
Researchers have discovered a new potential therapy that can protect transplanted human pancreatic islets from dying. The study suggests that pretreating cells with a peptide hormone called cholecystokinin (CCK) may enhance the curative potential of islet transplant for Type 1 diabetes.
Studies presented at the Eighth Annual PPSSC Conference showcased advancements in targeting stem cells, adipose-derived stem cell plasticity, and melanoma immunotherapy using genetically engineered iPSCs. These breakthroughs hold promise for developing effective treatments for regenerative medicine and cancer
Scientists have created a new technology that converts adult tissue-derived stem cells into human neurons on 3-D scaffolds, which were injected into mouse brains with promising results. The goal is to develop a dense circuitry of neurons that can replace diseased cells and improve therapeutic benefits.
Researchers developed a 3D micro-scaffold technology that promotes reprogramming of stem cells into neurons and supports growth of neuronal connections. The system improved cell-survival rates by nearly 40-fold compared to individual cell injections, enabling the potential treatment for human neurodegenerative disorders.
Researchers present innovative approaches using cell transplantation and genetic engineering to address neurodegenerative diseases, including Alzheimer's and Huntington's. Studies show promise in reducing learning deficits and alleviating peripheral neuropathic pain, offering new hope for treatment options.
Researchers at Kyoto University discovered that heart cells differentiated from induced pluripotent stem (iPS) cells can be used to treat damaged hearts. The study found an optimal maturation stage for heart cells, which is crucial for improving patient outcomes and reducing the number of cells required for therapy.
Researchers found that soaking islet cells in Anti-aging Glycopeptide (AAGP) protects them from tacrolimus, a toxic drug commonly used during transplants. This allows for fewer cells to be used, potentially treating more patients with the Edmonton Protocol.
Researchers have developed a novel cell transplantation delivery method using magnetic fields to guide human neural progenitor cells to injured brain areas. The iron-oxide nanoparticles help retain transplanted cells at the injury site, enhancing their viability and differentiation.
A University of California, Irvine study found that neural stem cells can improve both motor and cognitive impairments associated with dementia with Lewy bodies. The treatment involves the production of brain-derived neurotrophic factor, which enhances dopamine- and glutamate-producing neurons.
Researchers found fetal cartilage-derived progenitor cells (FCPCs) have superior cartilage repair capabilities than mesenchymal stem cells (MSCs). FCPCs showed yields approximately 24 times greater and possess self-renewal and multi-lineage differentiation abilities.
Researchers at UI Health have successfully transplanted stem cells from healthy siblings into adult patients with sickle cell disease, achieving a 92% cure rate and eliminating the need for chemotherapy. The procedure offers a new prospect for adults with the disease, who previously had limited treatment options.
Researchers found that human umbilical cord blood-derived monocytes improved hippocampal-dependent learning, memory, and motor function in AD modeled mice. The study suggests that these cells may exert therapeutic effects through phagocytosis of dead cells and cellular debris.
Researchers tested a new liver transplantation procedure using multi-layered sheets of hepatocytes and fibroblasts, which improved liver function in test animals for at least two months. The method showed higher albumin expression levels and better survival rates compared to traditional methods.
Researchers at Boston Children's Hospital have identified epoxyeicosatrienoic acids (EETs) that enhance stem cell engraftment in zebrafish and mice. These compounds could improve bone marrow transplants by allowing the use of more umbilical cord blood units, increasing patient chances of finding a matched donor.
Researchers used iPSC-derived renal progenitors to treat acute kidney injury in mice, showing improved recovery with reduced fibrosis and necrosis. The study's findings suggest that paracrine actions of the cells, rather than integration, led to therapeutic effects.
Researchers found that mesenchymal stem cells alleviate inflammation and nephritis in mice with SLE, suggesting a potential treatment for severe autoimmune diseases. The study showed that MSCs suppress T helper cell development, which helps to slow disease progression.
A new method has been discovered to culture stem cells, allowing them to grow twice as fast and be more efficient in regulating the immune response. This breakthrough could lead to more effective treatments for transplant patients by reducing side effects of current immunosuppressant drugs.
Diabetic neuropathy, a condition affecting up to 60% of diabetes patients, can be reversed by stem cell injections that promote angiogenesis and nerve re-myelination. Researchers have identified new mechanisms by which mesenchymal stem cells can improve the condition.
Researchers found modest improvements in patients with spinal cord injury treated with olfactory mucosa transplants, showing 'promising and safe' results. The study demonstrated benefits in ASIA sensory scores, bladder compliance, sensation, and daily life activities.
Researchers at Uppsala University have made significant progress in using stem cells to treat spinal cord injuries. Human stem cells transplanted into injured mice restored damaged sensory nerve connections, enabling long-term recovery of sensory functions.
A new study found that younger, unrelated donors with high T cell counts, particularly CD8 cells, resulted in significantly reduced disease relapse and improved survival rates for older patients. Screening for donor T cell characteristics may help optimize donor selection for these transplants.
Researchers successfully reactivated plasticity in adult brains by transplanting GABA neurons, allowing for vigorous rewiring and improved vision in amblyopic mice. The findings hold promise for future clinical applications and therapies for incurable brain disorders.
Researchers used bone marrow-derived mesenchymal stem cells to treat fractures, lung injury, and renal obstruction. The cells promoted fracture healing in rats and attenuated acute lung injury in mice. They also showed therapeutic effects in treating pulmonary and extrapulmonary acute lung injury.
Researchers have made significant progress in cell transplantation therapy, demonstrating improved outcomes for patients with complete spinal cord injury and potential treatments for Parkinson's disease. Studies also show that human pluripotent stem cells hold promise for treating the disease.
Researchers at RIKEN have developed a novel method for preserving donor livers, significantly extending their viability and improving transplant outcomes. By cooling organs to 22°C and supplementing with red blood cells, the team achieved remarkable success rates, even with organs obtained after cardiac arrest.
Researchers have successfully used autologous fat cell transplants to improve symptoms of osteoarthritis in patients. The treatment showed significant improvements in pain management and joint mobility, with most patients experiencing a minimum of 50% score improvement after 12 months.
A new study comparing gene therapy to half-matched transplants for SCID-X1 reveals that gene therapy leads to faster immune development, fewer infections, and reduced hospitalizations. Gene therapy shows promise as a viable alternative treatment for infants with this rare immune disorder.
Columbia University researchers have identified a unique set of patient-specific T cells that react to donor tissue, increasing in number before rejection but decreasing after acceptance. The study supports combining kidney and bone marrow transplants to reduce organ rejection and potentially eliminate lifelong immunosuppression.
Researchers have found that local implants of autologous adipose tissue-derived cells resulted in significant pain reduction and healing within two to seven weeks for all patients with long-lasting, non-healing digital ulcers. The treatment showed promise as an alternative to traditional therapies.
Researchers developed a 3D-printed carrier that retains its shape and integrity, delivering immunosuppressive drug cyclosporine A and cells for local and sustained release. The system overcomes existing delivery limitations, providing a promising solution for treating diseases requiring cell-based therapy.
Researchers report a breakthrough in treating hypophosphatasia, a fatal genetic bone disease, by combining bone marrow transplants with mesenchymal stem cell transplants. The treatment has shown promising results in improving bone mineralization and survival rates for infants with severe hypophosphatasia.
Researchers are using novel methods to understand how nerve cells form new connections after spinal cord injury, with the goal of restoring function and movement. A five-year NIH grant will allow them to isolate specific cell types and study their growth and interactions.
After a small number of MS patients received high-dose immunosuppressive therapy and then transplanted with their own hematopoietic stem cells, most sustained remission of active relapsing-remitting MS. Improvements in neurological function, quality-of-life, and functional scores were also noted.
Researchers at the University of Pennsylvania School of Medicine have successfully restored type 1 diabetics' ability to recognize low blood sugar levels after receiving islet cell transplantation. The treatment has nearly abolished time spent in a hypoglycemic state and improved response to experimental insulin-induced hypoglycemia.